Sakar Healthcare
Yest Low - 230
Today's Low - 235
Recent 15 days Low - 225
Stock trying to form a Good Base for next Upmove
More strength on close above 250
Yest Low - 230
Today's Low - 235
Recent 15 days Low - 225
Stock trying to form a Good Base for next Upmove
More strength on close above 250
🔅Sakar Healthcare is a pharmaceutical company incorporated in 2004. They do contract manufacturing majorly for sterile drugs and they also export to various emerging markets under their own brands
🔅Sakar Healthcare manufacture a variety of dosage forms including Liquid Injections, Lyophilized Injections, Dry Powder Injections, Dry Powder Syrups and Oral Solids Like Tablets and Capsules. Their biggest therapy area is Antibiotics which contributes to 41% of revenues,followed by Vitamins (15%), Antimalarial (14%), Anti infectives (5%), Antacid (4%) and Laxative (4%). In antibiotics, the majority of their revenues come from the Cephalosporins.
🔶Business Segments:
Sakar has 3 business segments viz. Contract Manufacturing(CMO), Exports and Loan Licensing. Under CMO, they manufacture drugs for big pharmaceutical companies including Zydus, Intas, Baxter, Torrent, Merck, Ferring Pharma, Ipca Labs, Indoco Remedies, etc.
Under the export segment, the sell drugs under their own brands to 53 countries in APAC, Latin America, East & French- West Africa, CIS, Europe, etc. They sell their products through over 75 distribution partners.
Under the Loan Licensing segment, they collect fees from customers for doing conversion and packaging of finished formulations.
🔶Foray into Oncology:
The company has entered the oncology segment by setting up a greenfield facility in Bavla, Gujarat - about 15 minutes away from the existing facility. It is an integrated facility with in-house R&D, API and formulation manufacturing.
They have installed modern technologies in this facility like flow chemistry and are trying to develop green chemistries. They will be manufacturing Oral Solids (Tablets and Capsules) and Injections (Liquid and Lyophilized).
The R&D, API and oral solids units have been commercialized and the injectables unit is expected to come online by March 2023. The OSD and API units have received WHO GMP approval.
They will be exporting the drugs under their own brands as well as contract manufacturing for their partners. The company has already signed an agreement with Zydus for the manufacture of oncology drugs
🔶Capex:
The company undertook a capex of ₹194 Cr for setting up the greenfield facility for oncology. To fund this capex, the company has availed debt of ₹95 Cr. They also raised funds through equity sale to Swiss PE fund - HBM Healthcare.
HBM initially invested ₹14.85 Cr in March 2021 and then invested ₹24 Cr in June 2022. The balance amount will be funded through internal accruals and promoter’s contribution. Management has said that they expect 3X asset turns from this capex.
🔶Guidance:
The management has said that they are expecting additional ₹600 Cr coming from oncology alone in 4-5 years with 30% EBITDA margins. They are aiming for a ₹500 Cr topline by 2026 with 60-65% revenues coming from oncology.
🔶Risks Involved :
The company will be facing a lot of competition from much larger companies in the oncology segment. Players like Natco Pharma have already commercialized all the molecules the company is planning to launch and operate in the same markets the company plans to sell its products. The promoters also have another company - Bisil Plast which is into PET bottle manufacturing and is not traded anymore.
🔅Sakar Healthcare manufacture a variety of dosage forms including Liquid Injections, Lyophilized Injections, Dry Powder Injections, Dry Powder Syrups and Oral Solids Like Tablets and Capsules. Their biggest therapy area is Antibiotics which contributes to 41% of revenues,followed by Vitamins (15%), Antimalarial (14%), Anti infectives (5%), Antacid (4%) and Laxative (4%). In antibiotics, the majority of their revenues come from the Cephalosporins.
🔶Business Segments:
Sakar has 3 business segments viz. Contract Manufacturing(CMO), Exports and Loan Licensing. Under CMO, they manufacture drugs for big pharmaceutical companies including Zydus, Intas, Baxter, Torrent, Merck, Ferring Pharma, Ipca Labs, Indoco Remedies, etc.
Under the export segment, the sell drugs under their own brands to 53 countries in APAC, Latin America, East & French- West Africa, CIS, Europe, etc. They sell their products through over 75 distribution partners.
Under the Loan Licensing segment, they collect fees from customers for doing conversion and packaging of finished formulations.
🔶Foray into Oncology:
The company has entered the oncology segment by setting up a greenfield facility in Bavla, Gujarat - about 15 minutes away from the existing facility. It is an integrated facility with in-house R&D, API and formulation manufacturing.
They have installed modern technologies in this facility like flow chemistry and are trying to develop green chemistries. They will be manufacturing Oral Solids (Tablets and Capsules) and Injections (Liquid and Lyophilized).
The R&D, API and oral solids units have been commercialized and the injectables unit is expected to come online by March 2023. The OSD and API units have received WHO GMP approval.
They will be exporting the drugs under their own brands as well as contract manufacturing for their partners. The company has already signed an agreement with Zydus for the manufacture of oncology drugs
🔶Capex:
The company undertook a capex of ₹194 Cr for setting up the greenfield facility for oncology. To fund this capex, the company has availed debt of ₹95 Cr. They also raised funds through equity sale to Swiss PE fund - HBM Healthcare.
HBM initially invested ₹14.85 Cr in March 2021 and then invested ₹24 Cr in June 2022. The balance amount will be funded through internal accruals and promoter’s contribution. Management has said that they expect 3X asset turns from this capex.
🔶Guidance:
The management has said that they are expecting additional ₹600 Cr coming from oncology alone in 4-5 years with 30% EBITDA margins. They are aiming for a ₹500 Cr topline by 2026 with 60-65% revenues coming from oncology.
🔶Risks Involved :
The company will be facing a lot of competition from much larger companies in the oncology segment. Players like Natco Pharma have already commercialized all the molecules the company is planning to launch and operate in the same markets the company plans to sell its products. The promoters also have another company - Bisil Plast which is into PET bottle manufacturing and is not traded anymore.
Wealthcreatures.com
TIMKEN FRESH ATH 2830 💚 Next 3189 & 3475+
TIMKEN INDIA 🇮🇳
20% 🆙 🔒 IN UC
3500 ➕️
Next Test Levels- 3776/4141/4500+
20% 🆙 🔒 IN UC
3500 ➕️
Next Test Levels- 3776/4141/4500+
Wealthcreatures.com
Best Agro Super Numbers
BEST AGRO
Launch of just 1 new product propelled sales by >100%, they have a pipeline of 27 new products to be introduced in coming years
Trading Cheap Vs Growth Outlook
Promoter bought from the open market yesterday
Stock is in uptrend
Launch of just 1 new product propelled sales by >100%, they have a pipeline of 27 new products to be introduced in coming years
Trading Cheap Vs Growth Outlook
Promoter bought from the open market yesterday
Stock is in uptrend
Wealthcreatures.com
Late update Best Agro Lows - 1329 Fresh ATH - 1457 Closed @ 1430 Recent Lows - 1271 on 14th Oct ( Our 1st Support zone ReTest @ 1290) Was 🆙 8% yesterday Coming out of almost 1 year of consolidation Now Ready for Fresh Upmove
BEST AGRO
Won't be suprised to see at 2500 - 3000+ in next 1 year
Won't be suprised to see at 2500 - 3000+ in next 1 year
Wealthcreatures.com
Lots of Query on Deepak fertliser It's Test Levels etc We expect Good Q2 numbers and possible 1500/1800 by next Diwali And In next 2 to 3 years won't be suprise to see it 3000+ Real Growth would start in 2024
DEEPAK FERTLISER
Cmp at Days Low - 760
Available at 30% Discount from ATH Of 1064
200 DMA around 710 - 715 zone
Shld Retest sub 700 zone and this can be buying opportunity
Add in SIP on Dips
Good Risk Reward Ratio
Can expect ATH again in next 2 to 4 Qtrs
One Good Qtr and stock can See Good RUN UP
Cmp at Days Low - 760
Available at 30% Discount from ATH Of 1064
200 DMA around 710 - 715 zone
Shld Retest sub 700 zone and this can be buying opportunity
Add in SIP on Dips
Good Risk Reward Ratio
Can expect ATH again in next 2 to 4 Qtrs
One Good Qtr and stock can See Good RUN UP
Wealthcreatures.com
TIMKEN INDIA 🇮🇳 20% 🆙 🔒 IN UC 3500 ➕️ Next Test Levels- 3776/4141/4500+
TIMKEN
Fresh ATH
3733 🎯
Fresh ATH
3733 🎯
Wealthcreatures.com
Sakar Healthcare Yest Low - 230 Today's Low - 235 Recent 15 days Low - 225 Stock trying to form a Good Base for next Upmove More strength on close above 250
Sakar Healthcare
Yest Lows - 225
Today's Low - 228.40
Yest Lows - 225
Today's Low - 228.40
On Radar
Indoco Remedies
Cmp - 375
Days Low - 369
Trading Near support zone - 350 - 360
The earnings power in Indoco Remedies should translate into even better earnings going forward. 2QFY23 earnings were inline.would watchout for FY23Q3 Nunbers
Favourable Risk Reward Ratio
S/L - 331 on cbsl or As per Risk
Midterm Test Levels- 425/460/500+
Longterm- 700/777+
Indoco Remedies
Cmp - 375
Days Low - 369
Trading Near support zone - 350 - 360
The earnings power in Indoco Remedies should translate into even better earnings going forward. 2QFY23 earnings were inline.would watchout for FY23Q3 Nunbers
Favourable Risk Reward Ratio
S/L - 331 on cbsl or As per Risk
Midterm Test Levels- 425/460/500+
Longterm- 700/777+